BioStock: New patent notice rounds off an eventful six months for Follicum
During the first half of 2020, Follicum has started, paused and resumed a phase II study with its primary candidate FOL-005. An international patent application has been filed regarding its newly developed topical formulation as a carrier of peptide drugs. New collaborations have been entered in regard to the company’s diabetes project and several patents have been obtained, most recently from the US Patent Office. As of now, the company has a solid IP protection for its peptides developed with the aim of treating diabetes and its complications, in both Europe and the United States, and the goal is to enter into strategic partnerships for the future clinical development of such peptides.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se